Siren LLC’s Pacira BioSciences PCRX Stock Holding History

Siren LLC’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-225,000	Closed	-$5.38M	–	125
2025 Q2	$5.38M	Buy	+225,000	New	+$5.67M	0.28%	62

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Siren LLC's PCRX Position: Q3 2025 in Review

Siren LLC sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 225,000 shares — an estimated $5.38M sold.

Siren LLC first reported a position in PCRX in Q2 2025 and held it in 1 quarter. The position peaked at $5.38M in Q2 2025. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

Siren LLC reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
Siren LLC sold 225,000 Pacira BioSciences shares in Q3 2025, an estimated $5.38M.
Siren LLC first reported a position in Pacira BioSciences in Q2 2025 and held it in 1 quarter.
Siren LLC's Pacira BioSciences position peaked at $5.38M in Q2 2025.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Siren LLC's 13F filing for Q3 2025, filed 13 Nov 2025.